U.S. markets closed
  • S&P Futures

    4,138.25
    -15.25 (-0.37%)
     
  • Dow Futures

    33,003.00
    -152.00 (-0.46%)
     
  • Nasdaq Futures

    14,015.00
    -20.00 (-0.14%)
     
  • Russell 2000 Futures

    2,218.70
    -11.90 (-0.53%)
     
  • Crude Oil

    72.34
    +0.70 (+0.98%)
     
  • Gold

    1,774.10
    +5.10 (+0.29%)
     
  • Silver

    25.98
    +0.01 (+0.04%)
     
  • EUR/USD

    1.1872
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • Vix

    20.70
    +2.95 (+16.62%)
     
  • GBP/USD

    1.3818
    +0.0009 (+0.06%)
     
  • USD/JPY

    110.0230
    -0.1270 (-0.12%)
     
  • BTC-USD

    35,224.79
    -274.42 (-0.77%)
     
  • CMC Crypto 200

    874.36
    -65.59 (-6.98%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    27,944.82
    -1,019.26 (-3.52%)
     

AstraZeneca's Imfinzi, Tremelimumab Combo Boosts Overall Survival In Lung Cancer

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • A combination of AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy has extended overall survival (OS) when used as a first-line treatment for stage IV (metastatic) non-small cell lung cancer (NSCLC).

  • A final analysis of data from the POSEIDON Phase 3 study shows that the combination demonstrated a statistically significant and clinically meaningful OS benefit versus chemotherapy alone.

  • The trial also tested a combination of Imfinzi plus chemotherapy, which, while showing a statistically significant improvement in progression-free survival (PFS) versus chemotherapy, failed to improve OS significantly.

  • Each combination demonstrated an acceptable safety profile, and no new safety signals were identified.

  • The data will be presented at a forthcoming medical meeting.

  • Price Action: AZN shares are up 0.62% at $53.81 during the market trading session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.